Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass spectrometry and multi-omics, has successfully raised hundreds of millions of renminbi in a Series C financing round. The funding round was led by GF Xinde Investment, with participation from Sun Rock Capital. The capital raised will be strategically allocated to accelerate the development of innovative products tailored to multi-omics application scenarios, bolster business development in technology services and biomedicine R&D, and support the company’s global market expansion efforts.
APTBIO, established in 2004, originated as the service platform of the Shanghai Institutes for Biological Sciences (SIBS). The company is renowned for its fully self-built multi-omics technology platform, which is the first of its kind in China. This comprehensive platform encompasses five omics platforms, including genomics, proteomics, metabolomics, single-cell omics, and spatial omics, positioning APTBIO at the forefront of multi-omics research and applications.
The successful Series C financing round underscores investor confidence in APTBIO’s innovative approach and its potential to transform life science technology services. With this influx of capital, APTBIO is well-equipped to advance its multi-omics technology platform, expand its service offerings, and strengthen its presence in the global market.- Flcube.com
